Randomized clinical trials in thrombotic thrombocytopenic purpura: Where do we go from here?

Transfusion

Volumn 46, Issue 10, 2006, Pages 1659-1662

  Kiss, Joseph E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMOTOSALEN; AUTOANTIBODY; FRESH FROZEN PLASMA; GLUCOCORTICOID; PREDNISONE; RITUXIMAB; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

CLINICAL TRIAL; CRYOPRECIPITATE; DEPOLYMERIZATION; EDITORIAL; HUMAN; INTERMETHOD COMPARISON; MOLECULAR SIZE; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PLASMA TRANSFUSION; PLASMAPHERESIS; PUVA; RELAPSE; REMISSION; SURVIVAL RATE; THROMBOCYTE; THROMBOTIC THROMBOCYTOPENIC PURPURA; ULTRAVIOLET A RADIATION;

DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFECTION CONTROL; MALE; PLASMA EXCHANGE; PSORALENS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; REMISSION INDUCTION; TIME FACTORS; ULTRAVIOLET RAYS;

EID: 33748940813     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.00986.x     Document Type: Editorial

References (31)

1. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-84.
2. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-94.
3. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589-600.
4. Vesely SK, George JN, Lammle B, et al. ADAMTS-13 activity in thrombotic thrombocytopenic purpura - hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective corhort of 142 patients. Blood 2003;102:60-8.
5. Fontana S, Kremer JA, Hovinga B, et al. Treatment of thrombotic thrombocytopenic purpura. Vox Sang 2006;90:245-54.
6. Rock GA. The management of thrombotic thrombocytopenic purpura in 2005. Semin Thromb Hemost 2005;31:709-17.
7. Bell WR, Braine JJ, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: clinical experience in 108 patients. N Engl J Med 1991;325:398-403.
8. Rock GA, Shuman KH, Buskard N, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991;325:393-7.
9. Henon P. Treatment of thrombotic thrombopenic purpura: results of a multicenter randomized clinical study. Presse Med 1991;20:1761-7.
10. Novitzky N, Jacobs P, Rosenstrauch W. The treatment of thrombotic thrombocytopenic purpura: plasma infusion or exchange? Br J Haematol 1994;87:317-20.
11. Coppo P, Bussel A, Charrier S, et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolyticuremic syndrome. Medicine (Baltimore) 2003;82:27-38.
12. Byrnes JJ, Moake JL, Klug P, Periman P. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am J Hematol 1990;34:169-74.
13. Owens MR, Sweeney JD, Tahhan RH, Fortkolt P. Influence of type of exchange fluid on survival in therapeutic apheresis for thrombotic thrombocytopenic purpura. J Clin Apher 1995;10:178-82.
14. Rock G, Shumak KH, Sutton DM, et al. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol 1996;94:383-6.
15. Zeigler ZR, Shadduck RK, Gryn J, et al. Cryopreciptitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher 2001;16:19-22.
16. Rock GA, Anderson D, Clark W, et al. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol 2005;129:79-86.
17. Mintz PD, Neff A, MacKenzie M, et al. A randomized, controlled phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006;46:1693-704.
18. Horowitz MS, Pehta JC. SD plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang 1998;74:231-5.
19. Yarranton H, Lawrie AS, Mackie IJ, et al. Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light. Transfusion 2005;45:1453-8.
20. Rock G, Moeslichan MZ, Benny B, et al. Solvent detergent treated plasma: an alternative to cryosupernatant plasma in thrombotic thrombocytopenic purpura [abstract]. Vox Sang 2005;89(S2):11.
21. Hellstern P, Muntean W, Schramm W, et al. Practical guidelines for clinical use of plasma. Thromb Res 2002;107:S53.
22. George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 2006;354:1927-35.
23. Rose M, Eldor A. High incidence of relapses in thrombotic thrombocytopenic purpura: clinical study of 38 subjects. Am J Med 1987;83:437-44.
24. Onundarson PT, Rowe JM, Heal JM, Francis CW. Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. Ann Intern Med 1992;152:791-6.
25. Bandarenko N, Brecher ME. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apher 1998;13:133-41.
26. Sarode R, Gottschall J, Aster RH, McFarland JG. Thrombotic thrombocytopenic purpura: Early and late responders. Am J Hematol 1997;54:102-7.
27. Howard MA, Williams LA, Terrell DR, et al. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2006;46:154-6.
28. Transfusion Medicine/Hemostasis Clinical Trials Network [homepage on the Internet]. Watertown (MA): The Network; c2006. Available from: http://www.tmhnetwork.org/
29. George JN, Woodson RD, Kiss JE, et al. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of Rituximab therapy for immune-mediated disorders. J Clin Apher 2006;21:49-56.
30. Yomtovian R, Niklinski W, Silver B, et al. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004;124:787-95.
31. Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005;106:1932-7.